Hartline Investment Corp Acquires New Stake in Zoetis Inc (ZTS)

Hartline Investment Corp acquired a new position in Zoetis Inc (NYSE:ZTS) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 75,728 shares of the company’s stock, valued at approximately $6,451,000. Zoetis comprises 1.7% of Hartline Investment Corp’s investment portfolio, making the stock its 16th largest holding.

Other hedge funds also recently bought and sold shares of the company. Dupont Capital Management Corp grew its holdings in shares of Zoetis by 2.5% in the second quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock worth $2,088,000 after purchasing an additional 601 shares during the last quarter. Dorsey Wright & Associates grew its holdings in shares of Zoetis by 7.9% in the second quarter. Dorsey Wright & Associates now owns 8,386 shares of the company’s stock worth $714,000 after purchasing an additional 617 shares during the last quarter. Wrapmanager Inc. grew its holdings in shares of Zoetis by 7.9% in the second quarter. Wrapmanager Inc. now owns 9,176 shares of the company’s stock worth $782,000 after purchasing an additional 672 shares during the last quarter. Wealthfront Inc. grew its holdings in shares of Zoetis by 4.4% in the first quarter. Wealthfront Inc. now owns 16,352 shares of the company’s stock worth $1,366,000 after purchasing an additional 688 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC grew its holdings in shares of Zoetis by 5.0% in the first quarter. Dynamic Advisor Solutions LLC now owns 14,968 shares of the company’s stock worth $1,250,000 after purchasing an additional 718 shares during the last quarter. Institutional investors own 89.76% of the company’s stock.

Shares of ZTS stock opened at $89.60 on Monday. Zoetis Inc has a 52 week low of $61.08 and a 52 week high of $93.67. The firm has a market capitalization of $43.17 billion, a P/E ratio of 37.33, a price-to-earnings-growth ratio of 1.84 and a beta of 1.02. The company has a quick ratio of 2.92, a current ratio of 4.38 and a debt-to-equity ratio of 2.50.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.06. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. The company had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.38 billion. During the same quarter last year, the firm posted $0.53 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. sell-side analysts anticipate that Zoetis Inc will post 3.07 EPS for the current fiscal year.

Several research analysts have recently issued reports on the stock. BMO Capital Markets restated a “hold” rating and issued a $82.00 target price on shares of Zoetis in a report on Thursday, August 2nd. Cantor Fitzgerald set a $98.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Thursday, August 2nd. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 target price on the stock. in a report on Tuesday, August 21st. They noted that the move was a valuation call. Argus raised their target price on shares of Zoetis from $90.00 to $103.00 and gave the stock a “buy” rating in a report on Tuesday, August 14th. Finally, Bank of America raised their target price on shares of Zoetis from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, July 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $90.53.

In other Zoetis news, insider Catherine A. Knupp sold 46,816 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $90.84, for a total transaction of $4,252,765.44. Following the completion of the transaction, the insider now owns 81,640 shares of the company’s stock, valued at $7,416,177.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Roman Trawicki sold 8,266 shares of the firm’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $92.53, for a total value of $764,852.98. The disclosure for this sale can be found here. Insiders sold 213,484 shares of company stock valued at $19,489,636 in the last ninety days. 0.35% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: What is the NASDAQ Stock Market?

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply